Skip to Content

Interpace Biosciences Inc IDXG

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Interpace Biosciences Inc is a growing leader in the life sciences industry. It provides complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. The activities of the company are functioned through two business units. The Interpace Diagnostics business unit which provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services and Interpace Pharma Solutions business supports clinical trials by providing lab testing, data management, project management, and biorepository services to biopharmaceutical companies.

Contact
300 Interpace Parkway, Building C
Parsippany, NJ, 07054
T +1 855 776-6419
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 152